SK Biopharmaceuticals Co Ltd
KRX:326030
SK Biopharmaceuticals Co Ltd
KRX:326030
Price:
103 500
KRW
-1.15%
Market Cap:
8.1T
KRW
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
Alert
SK Biopharmaceuticals Co Ltd
103500
-1200 (-1.15%)
| 52 Week Range |
75 700
125 900
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
SK Biopharmaceuticals Co Ltd
Income Statement
Earnings Waterfall
SK Biopharmaceuticals Co Ltd
SK Biopharmaceuticals Co Ltd
|
Revenue
|
511.3B
KRW
|
|
Cost of Revenue
|
-51.2B
KRW
|
|
Gross Profit
|
460.1B
KRW
|
|
Operating Expenses
|
-392.8B
KRW
|
|
Operating Income
|
67.3B
KRW
|
|
Other Expenses
|
-9.9B
KRW
|
|
Net Income
|
57.4B
KRW
|
Income Statement
SK Biopharmaceuticals Co Ltd
SK Biopharmaceuticals Co Ltd
Currency: KRW
| Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||
| Revenue |
123 852
N/A
|
10 717
-91%
|
6 274
-41%
|
10 115
+61%
|
25 999
+157%
|
162 060
+523%
|
183 964
+14%
|
203 992
+11%
|
418 645
+105%
|
319 801
-24%
|
349 264
+9%
|
414 148
+19%
|
246 179
-41%
|
265 819
+8%
|
289 399
+9%
|
290 903
+1%
|
354 892
+22%
|
408 082
+15%
|
465 064
+14%
|
511 328
+10%
|
|
| Gross Profit | |||||||||||||||||||||
| Cost of Revenue |
(514)
|
(916)
|
(1 653)
|
(1 985)
|
(1 974)
|
(3 419)
|
(4 693)
|
(6 581)
|
(22 336)
|
(26 501)
|
(32 372)
|
(43 390)
|
(37 768)
|
(35 695)
|
(37 114)
|
(30 671)
|
(34 082)
|
(42 090)
|
(41 461)
|
(51 198)
|
|
| Gross Profit |
123 338
N/A
|
9 801
-92%
|
4 621
-53%
|
8 130
+76%
|
24 025
+196%
|
158 641
+560%
|
179 271
+13%
|
197 410
+10%
|
396 309
+101%
|
293 300
-26%
|
316 893
+8%
|
370 758
+17%
|
208 411
-44%
|
230 124
+10%
|
252 285
+10%
|
260 232
+3%
|
320 809
+23%
|
365 992
+14%
|
423 603
+16%
|
460 130
+9%
|
|
| Operating Income | |||||||||||||||||||||
| Operating Expenses |
(202 597)
|
(229 844)
|
(242 143)
|
(258 168)
|
(263 524)
|
(257 090)
|
(284 966)
|
(290 007)
|
(301 350)
|
(311 411)
|
(309 995)
|
(323 169)
|
(339 489)
|
(346 720)
|
(331 569)
|
(357 157)
|
(358 331)
|
(370 562)
|
(383 192)
|
(392 831)
|
|
| Selling, General & Administrative |
(22 615)
|
(56 682)
|
(83 883)
|
(96 759)
|
(145 577)
|
(139 715)
|
(157 325)
|
(161 995)
|
(176 567)
|
(187 007)
|
(184 412)
|
(195 744)
|
(205 113)
|
(209 192)
|
(210 195)
|
(211 829)
|
(208 771)
|
(213 411)
|
(213 910)
|
(220 251)
|
|
| Research & Development |
(176 213)
|
(168 619)
|
(154 556)
|
(155 759)
|
(108 441)
|
(75 948)
|
(85 702)
|
(86 397)
|
(113 142)
|
(113 560)
|
(114 122)
|
(115 247)
|
(121 392)
|
(124 316)
|
(124 018)
|
(131 158)
|
(134 243)
|
(140 843)
|
(152 149)
|
(151 953)
|
|
| Depreciation & Amortization |
(3 769)
|
(4 544)
|
(5 653)
|
(7 627)
|
(9 506)
|
(10 245)
|
(10 755)
|
(10 432)
|
(11 642)
|
(10 844)
|
(11 460)
|
(12 178)
|
(12 984)
|
(13 212)
|
(13 532)
|
(14 170)
|
(15 317)
|
(16 309)
|
(17 132)
|
(17 459)
|
|
| Other Operating Expenses |
0
|
0
|
1 949
|
1 977
|
0
|
(31 183)
|
(31 183)
|
(31 183)
|
0
|
0
|
0
|
0
|
0
|
0
|
16 176
|
0
|
0
|
0
|
0
|
(3 168)
|
|
| Operating Income |
(79 259)
N/A
|
(220 043)
-178%
|
(237 523)
-8%
|
(250 039)
-5%
|
(239 499)
+4%
|
(98 450)
+59%
|
(105 695)
-7%
|
(92 597)
+12%
|
94 958
N/A
|
(18 111)
N/A
|
6 898
N/A
|
47 588
+590%
|
(131 078)
N/A
|
(116 596)
+11%
|
(79 285)
+32%
|
(96 925)
-22%
|
(37 522)
+61%
|
(4 570)
+88%
|
40 411
N/A
|
67 299
+67%
|
|
| Pre-Tax Income | |||||||||||||||||||||
| Interest Income Expense |
(2 645)
|
(2 290)
|
(2 519)
|
(2 101)
|
140
|
4 214
|
5 089
|
10 021
|
(72 438)
|
(73 709)
|
(76 774)
|
(89 725)
|
(15 452)
|
(9 554)
|
(11 375)
|
(9 381)
|
(11 486)
|
(21 900)
|
(20 018)
|
(24 425)
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
50 350
|
50 350
|
50 350
|
49 269
|
(824)
|
(824)
|
(824)
|
4 317
|
16 176
|
0
|
12 536
|
5 308
|
(6 808)
|
(6 808)
|
0
|
|
| Gain/Loss on Disposition of Assets |
(2 007)
|
(2 007)
|
0
|
(2 007)
|
(0)
|
(3)
|
(3)
|
(3)
|
(3)
|
0
|
(9)
|
(10)
|
(11)
|
0
|
(12)
|
(12)
|
(19)
|
0
|
162
|
162
|
|
| Total Other Income |
(541)
|
(248)
|
(1 816)
|
(519)
|
(550)
|
(570)
|
(1 032)
|
(520)
|
(509)
|
(450)
|
(413)
|
(269)
|
(245)
|
21
|
(44)
|
(139)
|
(139)
|
(327)
|
1 494
|
1 531
|
|
| Pre-Tax Income |
(84 451)
N/A
|
(224 589)
-166%
|
(241 858)
-8%
|
(254 666)
-5%
|
(239 909)
+6%
|
(44 459)
+81%
|
(51 290)
-15%
|
(32 749)
+36%
|
71 277
N/A
|
(93 095)
N/A
|
(71 123)
+24%
|
(43 239)
+39%
|
(142 469)
-229%
|
(109 953)
+23%
|
(90 715)
+17%
|
(93 921)
-4%
|
(43 858)
+53%
|
(33 605)
+23%
|
15 243
N/A
|
44 568
+192%
|
|
| Net Income | |||||||||||||||||||||
| Tax Provision |
12 932
|
12 045
|
12 321
|
12 299
|
(7 504)
|
(7 369)
|
(7 905)
|
(7 647)
|
(6 431)
|
(6 255)
|
(6 634)
|
(5 206)
|
3 038
|
3 359
|
6 182
|
5 936
|
8 478
|
10 293
|
9 345
|
4 742
|
|
| Income from Continuing Operations |
(71 519)
|
(212 544)
|
(229 537)
|
(242 367)
|
(247 414)
|
(51 828)
|
(59 196)
|
(40 396)
|
64 846
|
(99 351)
|
(77 756)
|
(48 445)
|
(139 431)
|
(106 594)
|
(84 533)
|
(87 985)
|
(35 379)
|
(23 313)
|
24 588
|
49 310
|
|
| Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4 483
|
2 497
|
5 631
|
9 209
|
8 072
|
|
| Net Income (Common) |
(71 519)
N/A
|
(212 544)
-197%
|
(229 537)
-8%
|
(242 367)
-6%
|
(247 414)
-2%
|
(51 828)
+79%
|
(59 196)
-14%
|
(40 396)
+32%
|
64 846
N/A
|
(99 351)
N/A
|
(77 756)
+22%
|
(48 445)
+38%
|
(139 431)
-188%
|
(106 594)
+24%
|
(84 533)
+21%
|
(83 502)
+1%
|
(32 883)
+61%
|
(17 682)
+46%
|
33 796
N/A
|
57 383
+70%
|
|
| EPS (Diluted) |
-1 100.3
N/A
|
-3 269.9
-197%
|
-3 531.33
-8%
|
-3 107.26
+12%
|
-3 447.52
-11%
|
-661.8
+81%
|
-755.88
-14%
|
-515.82
+32%
|
828.03
N/A
|
-1 268.63
N/A
|
-992.89
+22%
|
-618.6
+38%
|
-1 780.43
-188%
|
-1 361.12
+24%
|
-1 079.42
+21%
|
-1 066.26
+1%
|
-419.89
+61%
|
-225.79
+46%
|
431.55
N/A
|
732.73
+70%
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
